DNLI position history
The shares of Denali Therapeutics (DNLI) that Palo Alto Investors LP reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2025 Q2: 239,809 shares, $3.4M, 0.71% of portfolio, New
- 2025 Q3: 408,006 shares, $5.9M, 1.1% of portfolio, Add +70.1%
- 2025 Q4: 641,239 shares, $11M, 1.5% of portfolio, Add +57.2%
- 2026 Q1: 234,582 shares, $4.5M, 0.69% of portfolio, Reduce −63.4%
- 2026 Q2: not held, Exit
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|